Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Environmental, genetic, and molecular features of prostate cancer.

Deutsch E, Maggiorella L, Eschwege P, Bourhis J, Soria JC, Abdulkarim B.

Lancet Oncol. 2004 May;5(5):303-13. Review.

PMID:
15120667
2.

Androgen receptor involvement in the progression of prostate cancer.

Suzuki H, Ueda T, Ichikawa T, Ito H.

Endocr Relat Cancer. 2003 Jun;10(2):209-16. Review.

3.

Early versus deferred androgen suppression in the treatment of advanced prostatic cancer.

Nair B, Wilt T, MacDonald R, Rutks I.

Cochrane Database Syst Rev. 2002;(1):CD003506. Review.

PMID:
11869665
4.

Signal transduction in prostate cancer progression.

Gioeli D.

Clin Sci (Lond). 2005 Apr;108(4):293-308. Review.

PMID:
15603554
5.

The biology of hormone refractory prostate cancer. Why does it develop?

Isaacs JT.

Urol Clin North Am. 1999 May;26(2):263-73. Review.

PMID:
10361549
6.

Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.

Taplin ME, Balk SP.

J Cell Biochem. 2004 Feb 15;91(3):483-90. Review.

PMID:
14755679
7.

[Role of androgen receptors in hormone-refractory prostate cancer: molecular basics and experimental therapy approaches].

Rinnab L, Hessenauer A, Schütz SV, Schmid E, Küfer R, Finter F, Hautmann RE, Spindler KD, Cronauer MV.

Urologe A. 2008 Mar;47(3):314-25. doi: 10.1007/s00120-008-1637-1. Review. German.

PMID:
18273598
8.
9.

The androgen receptor gene and its influence on the development and progression of prostate cancer.

Montgomery JS, Price DK, Figg WD.

J Pathol. 2001 Sep;195(2):138-46. Review.

PMID:
11592091
10.

Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.

Niu Y, Chang TM, Yeh S, Ma WL, Wang YZ, Chang C.

Oncogene. 2010 Jun 24;29(25):3593-604. doi: 10.1038/onc.2010.121. Epub 2010 May 3. Review.

PMID:
20440270
11.

Genetic aspects of prostate cancer.

Latil A, Lidereau R.

Virchows Arch. 1998 May;432(5):389-406. Review.

PMID:
9645438
12.
13.

[Keyrole of endocrinology in the victory against prostate cancer].

Labrie F.

Bull Cancer. 2006 Sep;93(9):949-58. Review. French.

14.

Hormone-refractory prostate cancer? Anti-androgen withdrawal and intermittent hormone therapy.

Sciarra A, Casale P, Colella D, Di Chiro C, Di Silverio F.

Scand J Urol Nephrol. 1999 Aug;33(4):211-6. Review.

PMID:
10515081
15.

Leptin and prostate: implications for cancer prevention--overview of genetics and molecular interactions.

Ribeiro R, Lopes C, Medeiros R.

Eur J Cancer Prev. 2004 Oct;13(5):359-68. Review.

PMID:
15452447
16.

Telomerase as a new target for the treatment of hormone-refractory prostate cancer.

Biroccio A, Leonetti C.

Endocr Relat Cancer. 2004 Sep;11(3):407-21. Review.

17.

Gene therapy strategies in prostate cancer.

Eder IE, Haag P, Bartsch G, Klocker H.

Curr Gene Ther. 2005 Feb;5(1):1-10. Review.

PMID:
15638707
18.

Progress in understanding androgen-independent prostate cancer (AIPC): a review of potential endocrine-mediated mechanisms.

Schröder FH.

Eur Urol. 2008 Jun;53(6):1129-37. doi: 10.1016/j.eururo.2008.01.049. Epub 2008 Jan 28. Review.

PMID:
18262723
19.

Progression of prostate cancer: multiple pathways to androgen independence.

Devlin HL, Mudryj M.

Cancer Lett. 2009 Feb 18;274(2):177-86. doi: 10.1016/j.canlet.2008.06.007. Epub 2008 Jul 25. Review.

PMID:
18657355
20.

Transition to androgen-independence in prostate cancer.

Navarro D, Luzardo OP, Fernández L, Chesa N, Díaz-Chico BN.

J Steroid Biochem Mol Biol. 2002 Jul;81(3):191-201. Review.

PMID:
12163131

Supplemental Content

Support Center